RESprotect regains pancreatic anticancer and a green light to resume development
This article was originally published in Scrip
Executive Summary
SciClone Pharmaceuticals has returned the North American rights to the anticancer drug RP101 to privately owned German oncology firm RESprotect which it obtained in 2007.